Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?

Vardan T Karamyan1

  • 1Department of Pharmaceutical Sciences and Center for Blood Brain Barrier Research, School of Pharmacy, TTUHSC, Amarillo, TX, USA.

Physiological Reports
|March 9, 2021
PubMed

Insights

A "vasoactive peptide storm" involving bradykinin, substance P, and neurotensin may drive severe COVID-19 complications. Targeting these peptides simultaneously could offer better therapeutic benefits than single-mechanism treatments for coronavirus disease 2019.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Pathophysiology

Background:

  • Coronavirus disease 2019 (COVID-19) poses significant global health and economic challenges.
  • Inflammation, particularly cytokine storm, is linked to severe COVID-19 complications.
  • Bradykinin dysregulation has been recently implicated in COVID-19 severity.

Purpose of the Study:

  • To explore molecular mechanisms underlying COVID-19 severity beyond the "cytokine storm" and "bradykinin storm."
  • To identify additional vasoactive peptides contributing to COVID-19 pathology.
  • To propose a novel therapeutic strategy targeting multiple peptidergic systems.

Main Methods:

  • Review of existing scientific literature and experimental observations.
  • Analysis of molecular pathways involved in inflammation and microvascular permeability.
  • Postulation of the role of specific peptidases in peptide accumulation.

Main Results:

  • Evidence suggests substance P and neurotensin, alongside bradykinin, contribute to microvascular permeability and inflammation in COVID-19.
  • Neurolysin (Nln) is postulated to play a role in the accumulation of these vasoactive peptides.
  • A "vasoactive peptide storm" is proposed as a key driver of COVID-19 pathology.

Conclusions:

  • The severity of COVID-19 may be driven by a "vasoactive peptide storm" involving bradykinin, substance P, and neurotensin.
  • Simultaneous inhibition of these three peptidergic systems may offer superior therapeutic advantages over targeting a single mechanism.
  • This review highlights a potential new avenue for developing effective COVID-19 treatments.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
663
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
181
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
550
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.6K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.4K